YZYingqian Zhu

Yingqian Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yingqian Zhu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An ADDIE Model-Based Training Program for Enhancing Public Health Competencies in General Practice Residency: Development, Validation, and Preliminary Evaluation

    by Jianli Ge, Xiaoliang Sun, Min Ding, Yang Li, Shasha Geng, Xin Chen, Yingqian Zhu, Xiaoming Sun, Chi Chen, Hua Jiang

    Background: General practitioners (GPs) play a pivotal role in delivering public health services at the primary care level, yet standardized residency training often inadequately addresses public health competency development. This study aimed to systematically develop a public health service capability training course for GP residents using the ADDIE model and to preliminarily evaluate its effectiveness. Methods: This study employed a non-randomized controlled trial design. A structured training program was developed following the five-phase ADDIE model. In the Analysis phase, competency gaps were identified through stakeholder needs assessment and literature review; in the Design phase, a 13-module curriculum was validated via two-round Delphi consensus (expert authority coefficient Cr = 0.921); in the Development phase, teaching materials, case libraries, and assessment tools were produced; the Implementation phase delivered the training through monthly 5-hour sessions over 13 months; and the Evaluation phase assessed outcomes using formative and phased assessments. The curriculum integrated case-based learning, problem-based learning, and simulation-based teaching. The intervention group (n = 32, 2023– 2024 cohort) received the ADDIE-based training, while the control group (n = 22, 2021– 2022 cohort) received conventional lecture-based training. Competencies were assessed at baseline, immediately post-training, and at 3-month follow-up, along with the annual Objective Structured Clinical Examination (OSCE, scored on a 100-point scale). Results: Within the intervention group (n= 32), formative assessment scores improved significantly from baseline to 3-month follow-up across all three domains (theoretical: 69.03 ± 6.65 to 84.59 ± 3.81; clinical: 67.40 ± 6.18 to 84.27 ± 3.30; practical: 74.78 ± 4.39 to 84.85 ± 3.76; all P < 0.001). For the phased assessment, the intervention group outperformed the historical control group (n = 22) on annual OSCE (71.88 ± 10.84 vs 62.07 ± 4.71; mean difference = 9.80, 95% CI: 4.29– 15.29; P = 0.039; Cohen’s d = 0.99), with greater improvement from baseline (Δ = 12.47 ± 4.27 vs 8.96 ± 3.51; P = 0.002; Cohen’s d = 0.82). Course satisfaction was high (mean 4.43– 4.83 on a 5-point scale). Conclusion: The ADDIE-based training program demonstrated preliminary feasibility and potential effectiveness in enhancing GP residents’ public health service competencies. However, as a single-center, non-randomized pilot study with a modest sample size, these findings should be interpreted cautiously.

  • Open Access

    Associations of C‐Reactive Protein‐Triglyceride Glucose Index and Estimated Pulse Wave Velocity With All‐Cause Mortality: A Nationwide Prospective Cohort Study

    by Huixiao Yuan, Qingqing Li, Lei Sun, Jianli Ge, Shasha Geng, Xin Chen, Yingqian Zhu, Hua Jiang, Yang Li

    Background and Aims: The combined prognostic value of metaflammation and vascular aging markers in cardiovascular‐kidney‐metabolic (CKM) syndrome is unclear. This study aimed to assess the independent and joint associations of the C‐reactive protein‐triglyceride glucose index (CTI) and estimated pulse wave velocity (ePWV) with all‐cause mortality. Methods: This prospective study included 7183 participants from the CHARLS 2011 survey (original cohort) and 9594 from 2015 (temporal sensitivity analysis cohort). Multivariable Cox models and restricted cubic splines were used. Joint effects were analyzed by median‐based groups, and mediation was tested using the KHB method. Results: During follow‐up, 906 deaths occurred in the original cohort. Each 1‐unit increase in CTI was associated with a 56% higher mortality risk (HR = 1.56, 95% CI: 1.37–1.77), and each 1 m/s increase in ePWV with an 11% higher risk (HR = 1.11, 95% CI: 1.05–1.18). The high CTI/high ePWV group had the highest risk (HR = 1.73, 95% CI: 1.31–2.29). ePWV mediated 6.48% of the CTI‐mortality association, while CTI mediated 2.62% of the ePWV‐mortality association. These findings were confirmed in the temporal sensitivity analysis. Conclusion: CTI and ePWV independently and jointly associate with increased all‐cause mortality. The observed bidirectional mediation suggests potentially interconnected pathways that warrant further investigation. Integrating these accessible biomarkers could improve risk stratification in CKM syndrome.

  • Open Access

    Multimorbidity in elderly patients with or without T2DM: A real-world cross-sectional analysis based on primary care and hospitalisation data

    by Yang Li, Shasha Geng, Huixiao Yuan, Jianli Ge, Qingqing Li, Xin Chen, Yingqian Zhu, Yue Liu, Xiaotong Guo, Xiaoli Wang, et al.

    Type 2 diabetes mellitus (T2DM) increases the global economic burden and risk of premature death [1]. Widespread use of medications such as aspirin and angiotensin-converting enzyme inhibitors (ACEIs) has progressively reduced the affected population’s risk of cardiovascular death and increased their life expectancy, leading to a higher likelihood of other age-related chronic diseases [2]. Many […]


  • Open Access

    Nephroprotective effect of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus and hypertension: a real-world population-based cohort study

    by Shasha Geng, Yang Li, Jianli Ge, Yue Liu, Qingqing Li, Xin Chen, Yingqian Zhu, Xiaotong Guo, Huixiao Yuan, Xiaoli Wang, et al.

    Objectives: This study aimed to investigate the nephroprotective effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes mellitus (T2DM) and hypertension based on real-world clinical data. The study aimed to provide a theoretical basis for evidence-based pharmacological treatment of chronic kidney disease in this population. Methods: The 'Health Cloud' platform of the Shanghai Municipal Health Commission was employed to identify and screen elderly patients with T2DM and hypertension. The propensity score matching cohort was further constructed to estimate the effect of SGLT2i on the risk of rapid decline in renal function (triangle eGFR <=-5 ml/min/1.73 m(2) or triangle eGFR%<=-5%). Multiple sensitivity analyses were conducted to assess the robustness of the results. Results: After propensity score matching, no significant differences of covariates were identified between the SGLT2i and non-SGLT2i groups. The results of multivariate logistic models demonstrated a consistent and inverse correlation between SGLT2i use and the risk of rapid eGFR decline, whether defined as triangle eGFR <=-5 ml/min/1.73 m(2) (OR = 0.60, 95% CI:0.38-0.96) or triangle eGFR%<=-5%(OR = 0.57, 95% CI:0.37-0.89). In the stratification of renin-angiotensin system inhibitor (RASi) treatment, SGLT2i was associated with a lower risk of rapid eGFR decline in the RASi group (all ORs < 1, p < 0.05), with no interaction between SGLT2i and RASi (all P for interaction > 0.05) detected. Conclusions: SGLT2i significantly reduced the risk of rapid eGFR decline in elderly patients with T2DM and hypertension, but the synergistic effect with RASi remains unclear.


  • Open Access

    Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study

    by Yingqian Zhu, Ce Huang, Liang Zheng, Qingqing Li, Jianli Ge, ShaSha Geng, Miaomiao Zhai, Xin Chen, Huixiao Yuan, Yang Li, et al.

    Background: Mesenchymal stem cells (MSCs) hold a great promise for cell-based therapy in the field of regenerative medicine. In this study, we aimed to evaluate the safety and efficacy of intravenous infusion of human umbilical cord-derived MSCs (HUC-MSCs) in patients with aging frailty. Methods: In this randomized, double-blind, placebo-controlled trial, participants diagnosed with aging frailty were randomly assigned to receive intravenous administrations of HUC-MSCs or placebo. All of serious adverse events and AEs were monitored to evaluate the safety of treatment during the 6-month follow-up. The primary efficacy endpoint was alteration of physical component scores (PCS) of SF-36 qualities of life at 6 months. The secondary outcomes including physical performance tests and pro-inflammatory cytokines, were also observed and compared at each follow-up visits. All evaluations were performed at 1 week, 1, 2, 3 and 6 months following the first intravenous infusion of HUC-MSCs. Results: In the MSCs group, significant improvements in PCS of SF-36 were observed from first post-treatment visit and sustained throughout the follow-up period, with greater changes compared to the placebo group (p = 0.042). EQ-VAS scores of MSCs group improved significantly at 2 month (p = 0.023) and continued until the end of the 6-month visit (p = 0.002) in comparison to the placebo group. The timed up and go (TUG) physical performance test revealed significant group difference and showed continual enhancements over 6 months (p < 0.05). MSC transplantation improved the function of 4-m walking test (4MWT) compared with the placebo group with a decrease of 2.05 s at 6 months of follow-up (p = 0.21). The measurement of grip strength revealed group difference with MSCs group demonstrating better performance, particularly at 6 months (p = 0.002). Inflammatory cytokines (TNF-α, IL-17) exhibited declines in MSCs group at 6 months compared to the placebo group (p = 0.034 and 0.033, respectively). There was no difference of incidence of AEs between the two groups. Conclusion: Intravenous transplantation of HUC-MSCs is a safe and effective therapeutic approach on aging frailty. The positive outcomes observed in improving quality of life, physical performance, and reducing chronic inflammation, suggest that HUC-MSC therapy may be a promising potential treatment option for aging frailty. Trial Registration: Clinicaltrial.gov; NCT04314011; https://clinicaltrials.gov/ct2/show/NCT04314011.


  • Open Access

    Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study

    by Yingqian Zhu, Ce Huang, Liang Zheng, Qingqing Li, Jianli Ge, Shasha Geng, Xin Chen, Huixiao Yuan, Yang Li, Wenwen Jia, et al.

    Background: Mesenchymal stem cell (MSC) based therapy holds great promise for cell-based therapy in regenerative medicine. In this study, we aimed to evaluate the safety and efficacy of intravenous infusion of human umbilical cord-derived MSCs (HUC-MSCs) in patients with aging frailty. Methods: In this randomized, double-blind, placebo-controlled trial, participants diagnosed with aging frailty were randomly assigned to receive intravenous administrations of HUC-MSCs or placebo. All of serious adverse events (SAEs) and AEs were monitored to evaluate the safety of treatment during the 6-month follow-up. The primary efficacy endpoint was alteration of physical component scores (PCS) of SF-36 qualities of life at 6 months. The secondary outcomes including physical performance tests and pro-inflammatory cytokines, were also observed and compared at each follow-up visits. All evaluations were performed at 1 week, 1, 2, 3 and 6 months following the first intravenous infusion of HUC-MSCs. Results: In the MSCs group, significant improvements in PCS of SF-36 were observed from first post-treatment visit and sustained throughout the follow-up period, with greater changes compared to the placebo group (p=0.042). EQ-VAS scores improved significantly at 2 month (p=0.023) and continued until the end of the 6-month visit (p=0.002) in comparison to the placebo group. The timed up and go (TUG) physical performance test revealed significant group difference and showed continual enhancements over 6 months (p<0.05). MSC transplantation improved the function of four-meter walking test (4MWT) compared with the placebo group with a decrease of 2.05s at 6 months of follow-up (p=0.21). The measurement of grip strength revealed group difference with MSCs group demonstrating better performance, particularly at 6 months (p=0.002). Inflammatory cytokines (TNF-a, IL-17) exhibited declines in MSCs group at 6 months compared to the placebo group (p=0.034 and 0.033, respectively). There was no difference of incidence of AEs between the two groups. Conclusion: Intravenous transplantation of HUC-MSCs is a safe and effective therapeutic approach on aging frailty. The positive outcomes observed in improving quality of life, physical performance and reducing chronic inflammation, suggest HUC-MSC therapy may be a promising potential treatment option for aging frailty. Trial Registration: Clinicaltrial.gov; NCT04314011; Registered 10 December, 2019; URL: https://clinicaltrials.gov/ct2/show/NCT04314011.

  • Open Access

    Geriatric Health Care During the COVID-19 Pandemic: Managing the Health Crisis

    by Yingqian Zhu, Yue Liu, Hua Jiang

    COVID-19 pandemic significantly threatens the health and well-being of older adults. Aging-related changes, including multimorbidity, weakened immunity and frailty, may make older people more susceptible to severe infection and place them at higher risk of morbidity and mortality from COVID-19. Various quarantine measures have been implemented to control the spread of COVID-19. Nevertheless, such social distancing has disrupted routine health care practices, such as accessibility of medical services and long-term continuous care services. The medical management of older adults with multimorbidity is significantly afflicted by COVID-19. Older persons with frailty or multiple chronic disease may poorly adapt to the altered health care system, having detrimental consequences on their physical and mental health. COVID-19 pandemic has posed great challenges to the health of older adults. We highlighted the difficulties and obstacles of older adults during this unprecedented time. Also, we provided potential strategies and recommendations for actions to mitigate the COVID-19 pandemic threats. Certain strategies like community primary health care, medication delivery and home care support are adopted by many health facilities and caregivers, whereas other services such as internet hospital and virtual medical care are promoted to be accessible in many regions. However, guidelines and policies based on high-quality data are still needed for better health promotion of older groups with increasing resilience during the COVID-19 pandemic.


  • Open Access

    Association between ambulatory blood pressure variability and frailty among older hypertensive patients

    by Yingqian Zhu, Xin Chen, ShaSha Geng, QingQing Li, Huixiao Yuan, Xi Zhou, Huan Li, Jinglan Li, Hua Jiang

    Frailty and hypertension often coexist and are increasingly prevalent with advancing age. Although hypertension is independently associated with frailty, whether high blood pressure variability affecting frailty is unclear. In this retrospective study, we consecutively enrolled elderly patients with essential hypertension undergoing 24‐hour ABPM. The frailty was assessed by a 38‐item frailty index. The parameters of blood pressure variability of ABPM, including ARV, coefficient of CV, SD, and weighed SD were calculated. Ordinal logistic regression was used to investigate the association between blood pressure variability and frailty. A total of 242 hypertensive patients were recruited and divided into the frail group, pre‐frail group, and non‐frail group. The overall magnitudes of BP variability, assessed by ARV, CV, SD, and weighed SD, were significantly greater in patients with frailty than those with pre‐frailty and non‐frailty. With adjustment for covariates, ARV of 24‐hour, diurnal, and nocturnal SBP were independently associated with frailty (24 hours, OR: 2.48, 95% CI: 2.01‐3.07; daytime, OR: 1.83, 95% CI: 1.60‐2.10; nighttime, OR: 1.19, 95% CI: 1.12‐1.27). The CV of 24‐hour, diurnal, and nocturnal SBP was independently associated with frailty in the study (24 hours, OR: 1.2, 95% CI: 1.05–3.07; daytime, OR: 1.19, 95% CI: 1.05‐1.34; nighttime, OR: 1.13, 95% CI: 1.03‐1.24). For SD and weighed SD, only 24‐hour systolic SD was independent risk factor associated with frailty (OR: 1.12, 95% CI: 1.01‐1.23). The greater blood pressure variability of SBP, particular ARV and CV, were independent risk factors associated with higher‐order frailty status. Longitudinal studies are needed to investigate the causality associations between hypertension and frailty.